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Summary
 
US11 and US2 encode gene products expressed early in the replicative cycle of human cy-
tomegalovirus (HCMV), which cause dislocation of human and murine major histocompatibil-
ity complex (MHC) class I molecules from the lumen of the endoplasmic reticulum to the cy-
tosol, where the class I heavy chains are rapidly degraded. Human histocompatibility leukocyte
antigens (HLA)-C and HLA-G are uniquely resistant to the effects of both US11 and US2 in a
human trophoblast cell line as well as in porcine endothelial cells stably transfected with human
class I genes. Dislocation and degradation of MHC class I heavy chains do not appear to in-
volve cell type–specific factors, as US11 and US2 are fully active in this xenogeneic model. Im-
portantly, trophoblasts HLA-G and HLA-C possess unique characteristics that allow their es-
cape from HCMV-associated MHC class I degradation. Trophoblast class I molecules could
serve not only to block recognition by natural killer cells, but also to guide virus-specific HLA-C–
and possibly HLA-G–restricted cytotoxic T-lymphocytes to their targets.
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D
 
uring human pregnancy, allogenic trophoblast cells
are exposed directly to maternal immune effector
cells. For many years, the absence of MHC-restricted re-
jection of the implanting trophoblast was attributed to the
lack of class I MHC expression on these cells. It is now
clear that trophoblast cells express both classical (HLA-C;
references 1–4) and nonclassical (HLA-G; references 5–9)
class I products. To date, the function of these molecules
and their involvement in creating an immunologically
privileged site at the maternal–fetal interface remains elu-
sive. Sequence similarity of HLA-G to HLA-A and -B
molecules suggests that HLA-G (7) may function in a man-
ner analogous to its classical counterparts: HLA-G may
have a role in antigen presentation (10–12) and/or in evad-
ing NK cell–mediated lysis (13, 14), although the existence
of HLA-G–restricted T cells in vivo remains to be estab-
lished. Trophoblast HLA-C locus products might have a
complementary or overlapping purpose. However, the
unique and limited localization of HLA-G (15–18), its re-
stricted polymorphism (19–23), and the known reduced
surface stability of HLA-C locus products (24–27) suggest
that human trophoblast MHC class I molecules may possess
attributes that allow a unique function at the maternal–fetal
interface.
Human cytomegalovirus (HCMV)
 
1
 
 is a common human
pathogen that typically causes morbidity only in the immu-
nocompromised host or when infection occurs during
pregnancy. HCMV infects trophoblast (28), it is a known
teratogen, and HCMV infection during pregnancy has
been linked to spontaneous pregnancy loss (29, 30). HCMV
has proven interesting from an immunologic viewpoint, as
the virus has developed a number of strategies that enable it
to evade immune detection (31, 32). Of interest for this re-
port, HCMV-infected cells synthesize two gene products
early in the HCMV infectious cycle, US2 and US11,
which cause the dislocation of newly synthesized class I
heavy chain from the endoplasmic reticulum (ER) to the
cytosol. Cytosolic class I heavy chains are deglycosylated by
 
1
 
Abbreviations used in this paper:
 
 CM, complete medium; ER, endoplasmic
reticulum; HCMV, human cytomegalovirus; MOI, multiplicity of infec-
tion.
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-glycanase, and rapidly degraded by the proteasome.
Therefore, US2 and US11 may be partly responsible for
the downregulation of MHC class I surface expression in
HCMV-infected cells (33, 34). These effects of US2 and
US11 have been reported for human HLA-A and -B locus
products, as well as for murine class I molecules expressed
in human cells. Allelic preferences have been described for
US2- and US11-mediated degradation of the murine class I
products (35). The effects of US11 and US2 on the tropho-
blast class I molecules HLA-G and HLA-C are of particular
interest, both to further delineate in humans the substrate
specificity of these viral gene products, and to evaluate po-
tentially unique characteristics of trophoblast MHC class I
products.
We report that, unlike any previously described murine
or human class I products, both HLA-G and HLA-C ap-
pear fully resistant to the rapid degradation associated with
the US11 and US2 HCMV gene products. This suggests
that trophoblast MHC class I molecules possess characteris-
tics that allow escape from HCMV-associated MHC class I
degradation, and could serve not only to block recognition
by NK cells, but also to guide virus-specific, HLA-C– or
HLA-G–restricted CTL to their targets.
 
Materials and Methods
 
Cell Lines.
 
The JEG 3 choriocarcinoma cell line was ob-
tained from American Type Culture Collection (Rockville,
MD). The porcine, bone marrow–derived stromal cell line 2A2,
immortalized by transformation with SV40 large T antigen, was
generated (36) and characterized. Both cell lines were maintained
in complete medium (CM):DME (Sigma Chemical Company,
St. Louis, MO) supplemented with 10% heat-inactivated fetal bo-
vine serum/calf serum (1:1 vol/vol; Sigma Chemical Co.), 2 mM
 
L
 
-glutamine, 1/1,000 dilution U/ml penicillin (GIBCO BRL,
Gaithersburg, MD), and 100 
 
m
 
g/ml Streptomycin (GIBCO
BRL). Cells were grown at 37
 
8
 
C in humidified air with 5% CO
 
2
 
to 
 
z
 
90% confluency before infection.
 
Transfection Experiments.
 
Stable transfection of 2A2 cells with
the full-length class I cDNAs encoding HLA-A2 or HLA-Cw3
resulting in surface expression was carried out as described (37).
HLA-G cDNA under the control of the SR
 
a
 
 promoter in the
expression vector pBJ5 containing a neomycin resistance gene
(14) was a kind gift from Dr. L. Pazmany (Harvard University,
Boston, MA). The 2A2 cells were selected in CM containing
0.25 mg/ml G418 (GIBCO BRL). Surface expression of HLA-G
on transfected 2A2 cells was established by indirect immunofluo-
rescence and flow cytometry using both the mAb W6/32 and the
allele-specific antibody 87G (kind gift from Dr. D.E. Geraghty,
Fred Hutchinson Cancer Research Center, Seattle, WA; data not
shown). HLA-expressing 2A2 clones (2A2-HLA-A2/8.3, 2A2-
HLA-Cw3/7, and 2A2-HLA-G/1.2) were obtained by FACS
 
Ò
 
sorting of G418-resistant, W6/32-positive 2A2 cells (FACS
 
Ò
 
 Star
Plus; Becton Dickinson Immunocytometry Systems, San Jose,
CA) and subcloning by limiting dilution in the presence of irradi-
ated (40 cGy) 2A2 feeder cells.
 
Antibodies.
 
W6/32 is a murine mAb recognizing the properly
folded heavy chain of class I MHC molecules when associated
with 
 
b
 
2
 
m (38–40). The polyclonal rabbit anti–mouse class I
heavy chain antiserum (RafHC) recognizes nonassembled and
unfolded murine heavy chains (35). The polyclonal rabbit anti–
human class I heavy chain antiserum (R
 
a
 
HC) was raised against
purified HLA-A2 and -B27 human class I heavy chains. This an-
tibody exhibits no detectable cross-reactivity with porcine class I
heavy chains. The polyclonal antiserum detecting US11 (
 
a
 
US11)
was raised against bacterially produced full-length US11; the anti-
serum detecting US2 (
 
a
 
US2) was raised against the luminal NH
 
2
 
-
terminal portion of US2, again produced in bacteria.
 
Viruses and Viral Infection.
 
Recombinant vaccinia viruses ex-
pressing murine K
 
b
 
 (lacking the cytoplasmic tail), murine D
 
d
 
,
US11, and US2 were a generous gift from J. Bennink and J.
Yewdell (National Institutes of Health, Bethesda, MD). Cells
were infected with recombinant vaccinia viruses at a multiplicity
of infection (MOI) of 5 for 1 h in 500 
 
m
 
l of PBS supplemented
with 10% BSA (Boehringer Mannheim, Indianapolis, IN) at
37
 
8
 
C. CM was then added to cultures for an additional 3 h at
37
 
8
 
C to allow viral replication and expression of recombinant
proteins. Carboxybenzyl-leucyl-leucyl-leucinal (aldehyde; ZL
 
3
 
H)
was synthesized as described (34). Cells were starved in the pres-
ence of 25 
 
m
 
M ZL
 
3
 
H in cysteine- and methionine-free DMEM
(Sigma Chemical Co.) for 45 min at 37
 
8
 
C before metabolic label-
ing and analysis. For double infections, JEG 3 cells were infected
with VVUS11 or VVUS2 at a MOI of 3 for 1 h at 37
 
8
 
C, fol-
lowed by the addition of VVK
 
b
 
 or VVD
 
d
 
 at a MOI of 3 for an
additional 1 h. Thereafter, CM was added and cells starved as de-
scribed above.
 
In Vitro Transcription and Translation.
 
In vitro transcription was
performed essentially as described (41) on 5 
 
m
 
g of the pSP72 plas-
mid (Promega Corp., Madison, WI) containing either cloned
HLA-A2, or JEG 3 cell–derived HLA-G or HLA-Cw
 
*
 
0401
cDNA. Templates were linearized at the HindIII (New England
Biolabs, Beverly, MA) restriction site downstream from the
HLA-C and HLA-G inserts. In vitro translations were performed
as described (41) in a total reaction mixture of 25 
 
m
 
l, containing
17.5 
 
m
 
l Flexi
 
Ô
 
 Rabbit Reticulocyte Lysate (Promega Corp.), 0.8
 
m
 
l KCl (2.5 M; Promega Corp.), 0.5 
 
m
 
l amino acid mixture mi-
nus methionine (1 mM; Promega Corp.), 2.5 
 
m
 
l [
 
35
 
S]methionine
(10 mCi/m, translation grade; Dupont, Boston, MA), 0.25 
 
m
 
l
RNase inhibitor (40 U/
 
m
 
l; Promega Corp.), 1.5 
 
m
 
l dog pancreas
microsomes and RNA. Translations were performed for 1.5–2 h
at 30
 
8
 
C.
 
Immunoprecipitation and Gel Electrophoresis.
 
Sedimented micro-
somes (4 min, 14,000 rpm) from in vitro translations were lysed
in 1% digitonin in 25 mM Hepes, 150 mM KOAc, pH 7.7 (Boeh-
ringer Mannheim Corp., Indianapolis, IN) and lysates precleared
with normal mouse serum as described (41). Immunoprecipita-
tions of the precleared lysates were performed using the mAb
W6/32, at 4
 
8
 
C for 1 h before the addition of 100 
 
m
 
l inactivated
 
Staphylococcus aureus
 
 (
 
Staph A
 
) for an additional 1 h at 4
 
8
 
C. The
immunoprecipitates were washed four times in ice-cold wash
buffer (0.2% digitonin in 25 mM Hepes, 150 mM KOAc, pH
7.7), resuspended in sample buffer (62.5 mM Tris-HCl, pH 6.8,
5% 2-ME, 10% glycerol, 4% SDS, and bromophenol blue) and
boiled at 95
 
8
 
C for 5 min before SDS-PAGE.
Pulse–chase analyses were performed on 
 
z
 
10 
 
3
 
 10
 
6
 
 metaboli-
cally labeled cells as described (42). Lysis and immunoprecipita-
tion techniques were performed as described for in vitro
 
 
 
trans-
lated products with two modifications: two additional normal
rabbit serum/normal mouse serum preclearing cycles were in-
cluded in the cellular samples, and cell lysates were normalized for
protein synthesis before loading on PAGE. When reimmunopre-
cipitation was performed, the Staph A pellet from primary immu-
noprecipitations was denatured by boiling in 
 
z
 
50 
 
m
 
l PBS plus 
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1.0% SDS for 10 min. The supernatant containing denatured an-
tigens was then transferred to 1.0 ml 1.0% NP-40 in water (final
SDS concentration 
 
z
 
0.1%). 10 
 
m
 
l 10% BSA and 5 
 
m
 
l RafHC
were added and the reaction was incubated for 45 min at 4
 
8
 
C.
Antibody/antigen complexes were then captured with 100 
 
m
 
l
 
Staph A
 
 for 45 min at 4
 
°
 
 C. Complexes were washed and dena-
tured as described above.
 
Results and Discussion
 
The immunoevasive strategies used by clinically impor-
tant viruses have been used as tools that allow us to better
understand the similarities and differences between tropho-
blast class I molecules and those present in nonreproductive
tissues (43). Surface expression of HLA-G and HLA-C
products in the trophoblast-derived cell line, JEG 3, is sus-
ceptible to inhibition by the HSV-encoded ICP47 product
(43), as previously described for classical class I molecules
(44–46). The mechanism for this downregulation involves
the abrogation of peptide loading of class I heavy chains in
the lumen of the ER, thereby causing ER retention of class
I complexes. Retention of HLA-G and HLA-C in the ER
of HSV-infected JEG 3 cells confirms the dependence of
trophoblast class I products on peptide loading for proper
maturation (12) and surface expression, consistent with
close structural and functional similarities to other classical
human class I molecules, such as HLA-A and -B.
Human cytomegalovirus is another pathogen known to
infect trophoblast (28) and to act as a teratogen. HCMV
has been associated with spontaneous pregnancy loss (29).
In contrast to our findings for HSV, however, the bio-
chemical effects of HCMV gene products on HLA-G and
HLA-C suggest that trophoblast MHC class I products pos-
sess novel characteristics of structure or trafficking, which
allow them to escape those immunoevasive strategies of
HCMV that involve the US11 and US2.
 
JEG 3-derived HLA-G and HLA-C Are Resistant to the
Rapid Degradation Associated with the HCMV Gene Products
US2 and US11.
 
JEG 3 cells (which express HLA-G and
HLA-Cw
 
*
 
0401) were infected either with a vaccinia virus
recombinant driving the expression of mouse K
 
b
 
 (known to
be sensitive to rapid degradation associated with US 11; ref-
erence 35), or with both a vaccinia virus driving K
 
b
 
 expres-
sion (VVK
 
b
 
) and a separate vaccinia virus recombinant driv-
ing the expression of the HCMV-protein, US11 (VVUS11;
Fig. 1). Infected cells were then metabolically labeled in a
pulse–chase experiment and lysates of these cells immuno-
precipitated sequentially with RafHC, 
 
a
 
US11, and W6/32
antibodies. Immunoprecipitates were analyzed by PAGE.
In the absence of VVUS11 infection, significant amounts
of K
 
b
 
 were detected with the anti-heavy chain reagent
(RafHC) at the end of both the pulse and the 30-min
chase. In contrast, in cells infected with VVUS11, despite
similar rates of synthesis of K
 
b
 
 heavy chains during the
pulse, nearly all K
 
b
 
 was degraded at the 30-min chase point.
W6/32 recognizes both HLA-G and HLA-C (3, 43, 47–
49), and W6/32 reactive, properly formed HLA-C and
HLA-G from JEG cells accumulate during the 30-min
chase, both in the absence and the presence of US11. No
US11-associated degradation of either HLA-C or HLA-G
was observed. Immunoprecipitation with the polyclonal
antibody 
 
a
 
US11 revealed the presence of US11 only in
VVUS11-infected cells. Similar experiments using VVUS2
revealed that HLA-G and HLA-C in JEG 3 cells were also
resistant to the rapid degradation of class I heavy chain typ-
ically associated with the HCMV gene product US2 (data
not shown).
 
Trophoblast MHC Class I Products Associate with 
 
b
 
2
 
m but
Not with US2 and US11.
 
To further evaluate the mecha-
nism underlying the unique resistance of trophoblast class I
molecules to degradation in the presence of both US11 and
US2, we addressed the physical association of US2 and
US11 with MHC class I products translated
 
 
 
in vitro.
HLA-A2 and trophoblast HLA-G and HLA-C locus prod-
ucts were cotranslated in vitro with the light chain 
 
b
 
2
 
m un-
der conditions promoting assembly, together with either
US11 or US2. The products of these translations were then
either denatured and analyzed directly by PAGE or lysed in
digitonin, immunoprecipitated with the mAb W6/32, and
the resultant immunoprecipitations analyzed by SDS-
PAGE (Fig. 2 
 
a
 
). For “direct load” samples, class I heavy
chain, US2, and 
 
b
 
2
 
m, were detected at the appropriate posi-
tions by SDS-PAGE. W6/32 immunoprecipitates of the
HLA-A2 translation mixture reveal HLA-A2, 
 
b
 
2
 
m, and
US2 coprecipitation, indicating the physical association of
these three components. In contrast, for both HLA-G and
HLA-C translation mixtures, W6/32 immunoprecipitated
only class I heavy chains and associated 
 
b
 
2
 
m. When the
amounts of US2 cotranslated with equivalent amounts of
HLA-G and 
 
b
 
2
 
m were optimized (Fig. 2 
 
b
 
), W6/32 still
immunoprecipitated only class I heavy chain and associated
Figure 1. HLA-G and HLA-Cw*0401 from JEG 3 trophoblast-derived
cells are not degraded in the presence of the HCMV gene product US11.
Approximately 107 JEG 3 cells were either infected with a vaccinia virus
expressing the murine class I heavy chain, Kb (lacking its cytoplasmic tail,
VVKb, MOI 5 5), or doubly infected with VVKb (MOI 5 5) and a vac-
cinia virus expressing the HCMV gene product US11 (VVUS11, MOI 5
5). Cells were metabolically pulse labeled for 15 min with [35S]methion-
ine and chased with unlabeled media for 0 and 30 min. Lysates of these
cells were sequentially immunoprecipitated with an antibody against
mouse heavy chain (RafHC), with W6/32, and with aUS11. 
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b
 
2
 
m, despite the translation of US2 in relative amounts
greater than or equal to those observed for HLA-A2/US2/
b2m cotranslations (Fig. 2 a). We observed similar results
for US11 (data not shown). In short, US2 and US11 failed
to be coimmunoprecipitated with HLA-C or HLA-G, in-
dicating their lack of association with trophoblast MHC
class I heavy chains in the in vitro system.
HLA-G and HLA-C Expressed Stably in the Porcine Endo-
thelial Cell Line, 2A2, Are Resistant to Rapid Degradation of
Class I Heavy Chain Associated with the HCMV Gene Products
US11 and US2. To rule out cell type-specific protection
of HLA-C and HLA-G from US11 and US2-associated
degradation in JEG 3 cells, the susceptibility to degradation
of human MHC class I locus products stably transfected
into 2A2 porcine cells was analyzed. HLA-A2–expressing
porcine cells (2A2-A2/8.3) were infected either with
VVUS2 or VVUS11. Metabolic labeling was conducted in
the presence of the proteasome inhibitor carboxybenzyl-
leucyl-leucyl-leucinal (ZL3H), which retards the degrada-
tion of dislocated class I heavy chains and results in the cy-
tosolic accumulation of an unfolded, deglycosylated class I
heavy chain intermediate (33, 34). RaHC recovered
HLA-A2 mainly in its glycosylated form at both 0 and 30
min of chase in uninfected 2A2-A2/8.3 cells (Fig. 3 a). In
contrast, in either VVUS2- or VVUS11-infected cells, ac-
cumulation of the HLA-A2 heavy chain intermediate oc-
curs at the 30-min chase point. RaHC immunoprecipitates
of metabolically labeled nontransfected, parental 2A2 cells
(2A2) demonstrate that this antibody does not cross-react
with endogenous porcine class I heavy chains. Thus, in the
transfected porcine cell model, HLA-A2 is susceptible to
rapid degradation associated with either US2 or US11. Im-
munoprecipitations with aUS2 and aUS11 antibodies
demonstrate expression of these molecules in infected cells
(Fig. 3 b). Results from 2A2-A2/8.3 cells confirm that the
porcine endothelial cell transfectant is an appropriate model
Figure 2. In vitro–translated
HLA-A2 associates with cotrans-
lated US2 and b2m; in vitro–
translated trophoblast MHC class
I heavy chains do not. (A) Hu-
man MHC class I heavy chains
(HLA-A2, HLA-G, and HLA-C)
were cotranslated in vitro with
human b2m and US2. Radioac-
tively labeled translation prod-
ucts were either separated di-
rectly by SDS-PAGE, or were
immunoprecipitated with W6/32
before electrophoretic analysis.
As indicated, components of the
cotranslation are present at the
anticipated position in the direct load samples. (B) US2 fails to be coprecipitated with HLA-G and b2m, despite optimization of the relative quantities of
translated heavy chain, b2m, and US2. Increasing amounts of transcribed US2 were added to the cotranslation mixture of HLA-G, b2m, and US2 to
allow relative quantities of class I heavy chain to US2 similar to those demonstrated for HLA-A2 in A. Lanes 1–4 represent separate translation mixtures
in which the amounts of transcribed HLA-G and b2m template were constant but transcribed US2 template was present at a ratio of 2:1, 5:1, 10:1, and 20:1,
respectively. W6/32 immunoprecipitation and electrophoresis were as described above.
Figure 3. HLA-A2 is de-
graded in porcine endothelial
cells in the presence of either
US2 or US11. Approximately
107 2A2-A2/8.3, HLA-A2–ex-
pressing porcine endothelial
cells were either infected with a
vaccinia virus driving the expres-
sion of US2 (VVUS2, MOI 5
5), with VVUS11 (MOI 5 5), or
left uninfected (Uninf). Cells
were pretreated with the protea-
some inhibitor, ZL3H, for 45
min, pulse labeled for 15 min
with [35S]methionine, and then
chased with unlabeled media for
0 and 30 min (all in the presence of ZL3H). Lysed cells were sequentially
immunoprecipitated with a polyclonal antibody against class I heavy
chain, RaHC, and with aUS11 and aUS2. 10 3 106 parental 2A2 cells
were included as a specificity control for the RaHC antibody and were
pretreated, pulse labeled, and lysed as above. These lysates were immuno-
precipitated with RaHC only. (A) Immunoprecipitations with the poly-
clonal anti–human MHC class I heavy chain antibody, RaHC. (B) Im-
munoprecipitations with polyclonal antibodies raised against US2 and
US11 (aUS2 and aUS11, respectively).
Figure 4. HLA-G stably ex-
pressed in porcine endothelial
cells is resistant to class I heavy
chain degradation associated
with US2 and US11. Identical
experiments to those described
for Fig. 3 were performed using
2A2-HLA-G/1.2 cells, a porcine
endothelial cell line stably trans-
fected with HLA-G. For these
experiments, primary RaHC
immunoprecipitates were reim-
munoprecipitated with RaHC
before SDS-PAGE. (A) Immu-
noprecipitations with the polyclonal anti–human MHC class I heavy
chain antibody, RaHC. (B) Immunoprecipitations with polyclonal anti-
bodies raised against US2 and US11 (aUS2 and aUS11, respectively).
Uninf, Uninfected.501 Schust et al.
for the study of US2- and of US11-associated immunoeva-
sion, and documents the HCMV-associated dislocation re-
action in a nonhuman cell system.
Similar experiments were then performed using porcine
endothelial cells transfected with HLA-G (2A2-G/1.2) and
HLA-Cw3 (2A2-Cw3/7). In contrast to the results ob-
tained with HLA-A2 transfectants, neither VVUS11 nor
VVUS2 infection affected the fate of the class I heavy
chains in HLA-G or -Cw3 transfectants (Figs. 4 a and 5 a).
In short, consistent with findings from JEG 3 cells, HLA-G
in porcine endothelial cells is resistant to US11- and to
US2-associated degradation. HLA-Cw3 is similarly resis-
tant to US11- and US2-associated degradation in this xe-
nogeneic model.
We have previously shown that the HLA-C locus prod-
uct isolated from JEG 3 cells is HLA-Cw*0401 (4). In JEG
3 cells, this product is resistant to US2 and US11. HLA-
Cw3 expressed in the porcine endothelial cells is similarly
resistant. Therefore, we propose that escape from disloca-
tion and degradation associated with the HCMV gene
products US2 and US11 may be a more generalized char-
acteristic of HLA-C locus products. Thus, HLA-G and
HLA-C locus products appear unlike any previously de-
scribed human or murine class I molecule, in that each can
evade the degradation associated with both US11 and US2.
The results presented here are of interest from several
viewpoints. First, we have shown that dislocation of MHC
class I heavy chain associated with the presence of the
HCMV gene products US2 and US11 can be detected in a
nonhuman model. Dislocation and degradation appear to
be neither cell type nor species specific. From the view-
point of the virologist, the resistance of HLA-G and HLA-C
to both US11 and US2 suggests that there might be yet an-
other product within the genome of HCMV involved in
interrupting surface expression of HLA-G and HLA-C lo-
cus products. Potential candidates might include US6,
which has been shown to inhibit the TAP complex in a
manner somewhat analogous to the HSV protein ICP47
(50–52), or US3, which has also been associated with re-
tention of class I heavy chain in the ER (53, 54). It is possi-
ble that another, yet to be described, product may be dedi-
cated to the specific elimination of trophoblast class I
products. The demonstrated lack of coimmunoprecipita-
tion of HLA-G and HLA-Cw*0401 with US11 and US2
prompt one to consider structural attributes that might dis-
allow either direct interaction or interactions via a molecu-
lar intermediate. The analysis reported here provides a
starting point for a more precise delineation of those ele-
ments of class I molecules recognized by US2 and US11.
Alternatively, and of interest to the reproductive biologist,
trophoblast MHC class I molecules may be uniquely resistant
to immunoevasive strategies used by HCMV. However, the
ability of HCMV to infect trophoblast cells (28) and the
association of HCMV infection during early pregnancy with
both teratogenesis and spontaneous pregnancy loss (29, 30)
argue against this. Nonetheless, the resistance of HLA-G and
HLA-C locus products to both US11- and US2-associated
degradation indicates that trophoblast class I products possess
characteristics of structure and/or processing that distinguish
them from other, classical MHC class I molecules. Could the
actions of viral products like US2 and US11 constitute a
selective force that favors evolution of HLA-G or -C like
products to counteract such viral strategies?
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Figure 5. HLA-Cw3 stably ex-
pressed in porcine endothelial cells
is resistant to class I heavy chain
degradation associated with US2
and US11. Identical experiments
to those described for Figs. 3 and
4 were performed using 2A2-
HLA-Cw3/7 cells, a porcine en-
dothelial cell line stably transfected
with HLA-Cw3. (A) Immuno-
precipitations with the polyclonal
anti–human MHC class I heavy
chain antibody, RaHC. (B) Im-
munoprecipitations with poly-
clonal antibodies raised against
US2 and US11 (aUS2 and
aUS11, respectively). Uninf, Un-
infected.502 Trophoblast Class I Molecules and Human Cytomegalovirus
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